Anna Friedel

Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I–III Clinical Trials

Ben Klünder, Rajendar K. Mittapalli, Mohamed‐Eslam F. Mohamed et al. · Clinical Pharmacokinetics · 2019 · 59 citations · Full text

Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure‐response analysis

Suresh Agarwal, Sathej Gopalakrishnan, Sven Mensing et al. · Hematological Oncology · 2019 · 41 citations

Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials

Ahmed Nader, Sven Stodtmann, Anna Friedel et al. · The Journal of Clinical Pharmacology · 2019 · 40 citations

An Integrated Population Pharmacokinetic Model Versus Individual Models of Depatuxizumab Mafodotin, an Anti‐EGFR Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Overexpress EGFR

Rajendar K. Mittapalli, Sven Stodtmann, Anna Friedel et al. · The Journal of Clinical Pharmacology · 2019 · 11 citations

Abstract Depatuxizumab Mafodotin, Solid Tumors, Overexpress Egfr +20